| Code | CSB-RA023603MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NI-0101, targeting Toll-like receptor 4 (TLR4), a pattern recognition receptor crucial for innate immune responses. TLR4 recognizes pathogen-associated molecular patterns, particularly lipopolysaccharide from Gram-negative bacteria, and damage-associated molecular patterns released during tissue injury. Upon activation, TLR4 initiates signaling cascades through MyD88-dependent and TRIF-dependent pathways, leading to production of pro-inflammatory cytokines and type I interferons. Dysregulated TLR4 signaling is implicated in sepsis, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, and various autoimmune conditions.
NI-0101 is a humanized IgG1 monoclonal antibody that specifically binds to the extracellular domain of TLR4, blocking ligand-induced receptor activation and downstream inflammatory responses. This biosimilar provides researchers with a valuable tool for investigating TLR4-mediated inflammatory pathways, studying innate immune mechanisms, and exploring therapeutic strategies for conditions characterized by excessive TLR4 activation. It supports studies in immunology, inflammation research, and infectious disease models.
There are currently no reviews for this product.